TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06764420

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine Oral Suspension
Description: Participants in this group will receive an oral suspension containing 5 grams of glutamine dissolved in cold water. This solution is administered 30 minutes before meals, three times per day, using the swish and swallow technique throughout the radiotherapy period. This control intervention serves to compare the effects of glutamine alone with the combined arginine and glutamine treatment. In addition to the glutamine suspension, patients in this group will receive general measures and analgesic drugs according to the WHO scale to manage symptoms of mucositis.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arginine and Glutamine Oral Suspension
Description: Participants in this group will receive an oral suspension containing 5 grams of arginine and 5 grams of glutamine dissolved in cold water. This solution is administered 30 minutes before meals, three times per day, using the swish and swallow technique throughout the radiotherapy period. The swish and swallow technique involves patients swishing the solution around the oral mucosa to ensure even distribution before swallowing. This intervention aims to evaluate the combined effect of arginine and glutamine on reducing the severity of radiation-induced mucositis, improving mucosal healing, and providing symptomatic relief.
Study: NCT06763601

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SSMP, Isometric exercise, eccentric exercise, heavy slow resistance , functional program
Description: In this group the patients will be given symptom modification procedure in the first phase followed by isometric exercises in second phase, eccentrics and HSR in third phase and functional program in fourth phase

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MWM,Isometric exercise, eccentric exercise, heavy slow resistance , functional program
Description: in this mobilization with movement in first phase will be given followed by isometrics, eccentrics and heavy slow resistance exercise and finally the functional program

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sham mobilization
Description: Sham mobilization followed by isometrics, eccentric training and heavy resistance training and finally the functional program .
Study: NCT06764537

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Blood collection (40 mL) in glioblastoma patients
Study: NCT06764290

Intervention type: OTHER
Intervention: pedal walking
Description: Pedal walking is a challenging walking task that can be used as a form of physical therapy for stroke participants.

Intervention type: OTHER
Intervention: visual occlusion
Description: Walking with eyes-covered is a challenging walking task that can be used as a form of physical therapy for stroke participants.
Study: NCT06763484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: 20 mg PO daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule starch
Study: NCT06764121

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Haskap Berry Powder
Description: The participants will consume four packets (16g) of haskap berry powder. The powder can be consumed with other food products.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Haskap Berry Powder
Description: The participants will consume four packets (16g) of haskap berry powder. The powder can be consumed with other food products.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Powder
Description: The participants will consume four packets (24g) of placebo powder. The powder can be consumed with other food products.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Powder
Description: The participants will consume four packets (24g) of placebo powder. The powder can be consumed with other food products.
Study: NCT06764082

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high MCT formula
Description: Energy Intake: The tube-feeding formula was a special medical-purpose formula food with high MCT and deep hydrolyzed milk protein (Alfare, Nestlé, Switzerland), which contained hydrolyzed whey protein, maltodextrin, vegetable oil, and MCT, etc. At a high-calorie concentration, each 1000 mL could provide 800 kcal, 15.8 g MCT, and 21.5 g protein (osmotic pressure 227 mOsm/kg).~Feeding Procedure: On the basis of 130 - 150% DRI, a high-calorie formula feeding amount of 160 ml/kg/d could provide 2.7 g/kg/d MCT. After the operation, starting from when oral nutrition was feasible, the amount gradually increased from the initial amount until the expected amount was reached, and this continued until 6 months after the operation. The difference between the estimated feeding amount and the actual feeding amount could be selectively supplemented with enteral nutrition (nasogastric tube).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: normal oral intake of the traditional formula
Description: For the children in the control group, there were no special restrictions before the operation. After they were able to have a normal diet postoperatively, they were encouraged to have a normal oral intake of the traditional formula. The recommended energy input for the formula was 130 - 150% of the reference intake (DRI) based on age and gender as per the World Health Organization (WHO). The final dosage and schedule were determined by the children and their parents or caregivers. The feeding route and the schedule for complementary feeding were the same as those in the experimental group.
Study: NCT06763666

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cladribine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT06763354

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gallium[68Ga]NOTA-DNA Multivalent SGC8 Injection
Description: On the examination bed, the patient was placed in the lying truncated position, the perineum was disinfected with a towel, and a double-lumen urinary catheter was inserted via the perineum.Inject 50ml saline to clean the bladder once, open the drainage bag to drain.1mci SGC8 was dissolved in 50ml physiological saline. The drainage bag was clamped shut and 50ml of developer was injected into the bladder through the catheter, followed by 10ml of gas or saline (all developer in the ureter was injected into the bladder. The catheter was closed for 1 hour, during which time the patient was placed in the flat position, left lateral position, right lateral position, and supine position changing positions every 15 minutes.After 1 hour, the drainage bag was opened, the bladder was emptied with radioactive fluid, and the urine bag was replaced.
Study: NCT06764173

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oat drink
Description: 6 dl of oat drink daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oat drink
Description: 6 dl of oat drink daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cow's milk
Description: 6 dl of cow's milk daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cow's milk
Description: 6 dl of cow's milk daily
Study: NCT06764199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Acceptance and Commitment Therapy (ACT), a relatively new psychotherapy, incorporates psychopathological hypotheses and interventions based on contextual behavioral sciences and Relational Frame Theory.
Study: NCT05655026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIV, HFNO
Description: Arterial blood pressure and saturation will be measured. Arterial blood gases will be collected to qualify patients to one of the three groups. After qualification, patient will be randomly assigned to a given respiratory support method during FB.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIV, HFNO
Description: Arterial blood pressure and saturation will be measured. Arterial blood gases will be collected to qualify patients to one of the three groups. After qualification, patient will be randomly assigned to a given respiratory support method during FB.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIV, HFNO
Description: Arterial blood pressure and saturation will be measured. Arterial blood gases will be collected to qualify patients to one of the three groups. After qualification, patient will be randomly assigned to a given respiratory support method during FB.
Study: NCT05654792

Intervention type: DEVICE
Intervention: Transcatheter aortic valve implantation
Description: Transcatheter aortic valve implantation in cases of severe aortic stenosis
Study: NCT03540355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cipros 20 association
Description: oral, once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crestor 20 mg
Description: Oral, once a day
Study: NCT06140901

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Study morphological and functional of respiratory epithelium
Description: The working's investigators hypothesis is that the morphology and functional of the epithelium of children with ADV or RV respiratory infection is different between those who progress to PIBO and those who do not.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Study morphological and functional of respiratory epithelium
Description: The working's investigators hypothesis is that the morphology and functional of the epithelium of children with ADV or RV respiratory infection is different between those who progress to PIBO and those who do not.
Study: NCT05716152

Intervention type: DIAGNOSTIC_TEST
Intervention: Morning blood sample and skin punch biopsy of 4 mm diameter.
Description: 1. Morning blood sample (8:00-10:00 am) will be obtained for assessment of Total Testosterone (TT), Free Testosterone (fT), Luteinizing hormone (LH), Follicle stimulating hormone (FSH), and Estradiol (E2).~2. Skin biopsy:~Skin punch biopsy of 4 mm diameter will be obtained from both psoriasis patients (from the lesional and non-lesional sites), and the control group (normal skin). Tissue specimens will be used for formation of Paraffin embedded blocks. Slides will be stained by routine Hematoxylin and Eosin stain. The expression of AR will be measured by immune and histochemical staining by the use of a mouse monoclonal antibody

Intervention type: DIAGNOSTIC_TEST
Intervention: Morning blood sample and skin punch biopsy of 4 mm diameter.
Description: 1. Morning blood sample (8:00-10:00 am) will be obtained for assessment of Total Testosterone (TT), Free Testosterone (fT), Luteinizing hormone (LH), Follicle stimulating hormone (FSH), and Estradiol (E2).~2. Skin biopsy:~Skin punch biopsy of 4 mm diameter will be obtained from both psoriasis patients (from the lesional and non-lesional sites), and the control group (normal skin). Tissue specimens will be used for formation of Paraffin embedded blocks. Slides will be stained by routine Hematoxylin and Eosin stain. The expression of AR will be measured by immune and histochemical staining by the use of a mouse monoclonal antibody
Study: NCT04297436

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 4CMenB (Bexsero®) vaccine
Description: Tthe 4CMenB vaccine (Bexsero®) contains the MeNZB OMV component plus three recombinant antigens (NadA, fHBP-GNA2091, and NHBA-GNA1030. The 4CMenB vaccine (Bexsero®) induces antibodies in humans that recognise gonococcal proteins.
Study: NCT05600998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Subjects will receive carilizumab every three weeks, with alozantinib 20 mg orally daily for 9 weeks
Study: NCT05600049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototypes (815-v1 001) to (815-v1 050)
Description: Application on brown spots located on the face and/or the hand (6 treatments during the study).~An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand.~Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype (815-v1 051) to (815-v1 100)
Description: Application on brown spots located on the face and/or the hand (6 treatments during the study.~An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand.~Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototypes (815-v1 101) to (815-v1 150)
Description: Application on brown spots located on the face and/or the hand (6 treatments during the study.~An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand.~Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototypes (815-v1 151) to (815-v1 200)
Description: Application on brown spots located on the face and/or the hand (6 treatments during the study.~An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand.~Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
Study: NCT06013943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab+Gemox
Description: All of drugs were used for 6-8 cycles at the combined treatment stage, then Envafolimab and Gemcitabine continued at maintenance treatment stage until disease progression as defined by RECIST1.1, unacceptable toxicity, withdrawal from the study or death, or no more than 1 years.~Combined treatment stage: Envafolimab(150mg, iH, Q1W, Day1)+Gemcitabine(1000mg/m2, iv, Q3W, Day1 and Day8)+Cisplatin(1000mg/m2, iv, Q3W, Day1 and Day8);~Caintenance treatment stage: Envafolimab(400mg, iH, Day1, Q3W)+Gemcitabine(1000mg/m2, po, Day1-14, Q3W).
Study: NCT05199363

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information leaflet
Description: Before examination study participant will obtain an information leaflet which includes descriptive and illustrative sections Information for young patients and their caregivers. What is Magnetic Resonance Imaging and what is the examination like?

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational movie
Description: Before examination study participant will be shown educational video with an radiology technologist and actors who role play the examination What is MRI and what is the examination like?

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Demonstration
Description: Before examination study participant will take a part in scenario-based demonstration with the use of props such as the scanner model and a multimedia presentation Scenario for a demonstration before a Magnetic Resonance examination for young patients and their caregivers
Study: NCT05926973

Intervention type: OTHER
Intervention: Enhanced cardiac arrest bundle
Description: * Delivering shocks with the LUCAS mechanical CPR device running~* After 5 shocks have been delivered placing new pads in the Anterior Posterior (AP) position~* Delivering shocks using the TVAA Tempus Pro defibrillator rather than the Ambulance Service defibrillator.
Study: NCT05005585

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate implant
Description: immediate implant placement with VST technique versus early implant placement with contour augmentation technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate implant
Description: immediate implant placement with VST technique versus early implant placement with contour augmentation technique
Study: NCT06347484

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EHR-informed Recruitment Method of Contact
Description: The intervention being studied here is the method of contact (patient portal vs. email vs. postal mail) after being identified in the EHR

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EHR-informed Recruitment Method of Contact
Description: The intervention being studied here is the method of contact (patient portal vs. email vs. postal mail) after being identified in the EHR

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EHR-informed Recruitment Method of Contact
Description: The intervention being studied here is the method of contact (patient portal vs. email vs. postal mail) after being identified in the EHR

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Text-Messages and Connection to Cardiovascular Research Opportunities
Description: All participants who enroll in CONNECT, regardless of method of contact, will receive educational text messages and connection to cardiovascular research opportunities. Text messages will be tailored and include content on cardiovascular health promotion and research participation.
Study: NCT06093048

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic retrograde cholangiopancreatography
Description: saftey and outcome in patients older than 65 years old

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic retrograde cholangiopancreatography
Description: saftey and outcome in patients older than 65 years old
Study: NCT04354012

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: methylene blue, gentian violet, and ovine forestomach wound dressings
Description: Hydrofera Blue is an antibacterial foam dressing that contains methylene blue and gentian violet to manage wounds. This is a safe, non-cytotoxic product that can be worn for 7 days while not inhibiting growth factors. This products wicks bacteria into the foam and away from the wound surface using natural negative pressure through capillary flow.~Endoform (ovine forestomach) is a natural dermal template used in all phases of wound healing. This product helps to stabilize, build, and organize tissue in acute and chronic wounds.~Hypafix tape aids in stabilization of wound dressings. This productIt is easy to apply, skin friendly, and comfortable to use.
Study: NCT06346821

Intervention type: DEVICE
Intervention: Optune® (Tumor Treating Fields)
Description: TTFields at 200 kHz to the brain using the Optune® System

Intervention type: DEVICE
Intervention: Optune® (Tumor Treating Fields)
Description: TTFields at 200 kHz to the brain using the Optune® System

Intervention type: DEVICE
Intervention: Optune® (Tumor Treating Fields)
Description: TTFields at 200 kHz to the brain using the Optune® System
Study: NCT05166538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: direct-acting oral P2Y12-receptor antagonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: platelet aggregation inhibitor
Study: NCT05898984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test product (T):CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI
Description: CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI with HFA 134a propellant (fixed combination of BDP \[200 μg\], FF \[6 μg\] and GB \[12.5 μg\] via pMDI): 4 inhalations alternated with 4 inhalations of CHF 5993 placebo, corresponding to 8 inhalations in total and giving a total daily dose (TDD) of BDP/FF/GB: 800/24/50 µg.~Reference product 1 (R1): CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI with HFA 134a propellant (fixed combination of BDP \[100 μg\], FF \[6 μg\] and GB \[12.5 μg\] via pMDI): 4 inhalations alternated with 4 inhalations of CHF 5993 placebo, corresponding to 8 inhalations in total and giving a TDD of BDP/FF/GB: 400/24/50 µg.~Reference product 2 (R2): BDP HFA (QVAR REDIHALER®, BDP 80 μg): pressurised, breath-actuated, metered dose aerosol with a dose counter): 8 inhalations (TDD of BDP: 640 µg ex-actuator, 800 µg ex valve).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference product 1 (R1): CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI
Description: with HFA 134a propellant (fixed combination of BDP \[100 μg\], FF \[6 μg\] and GB \[12.5 μg\] via pMDI): 4 inhalations alternated with 4 inhalations of CHF 5993 placebo, corresponding to 8 inhalations in total and giving a TDD of BDP/FF/GB: 400/24/50 µg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference product 2 (R2): BDP HFA (QVAR REDIHALER®, BDP 80 μg)
Description: pressurised, breath-actuated, metered dose aerosol with a dose counter): 8 inhalations (TDD of BDP: 640 µg ex-actuator, 800 µg ex valve).
Study: NCT04884360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib tablets 300 mg oral twice daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo tablets taken orally at a dose of 300 mg twice daily
Study: NCT06294366

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar Bowa device
Description: Bipolar Bowa device used in prostatic resection and enucleation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar Bowa device
Description: Bipolar Bowa device used in prostatic resection and enucleation
Study: NCT06388616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balcinrenone
Description: 50 mg, Immediate release capsule to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balcinrenone
Description: 50 mg, Immediate release capsule to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balcinrenone
Description: 50 mg, Immediate release capsule to be taken orally.
Study: NCT04237103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: oral capsules taken once a week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Administered identically to the experimental group